Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Payables (2016 - 2025)

Historic Payables for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $458.1 million.

  • Dr Reddys Laboratories' Payables changed N/A to $458.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $458.1 million, marking a year-over-year change of. This contributed to the annual value of $862.0 million for FY2025, which is 6450.38% up from last year.
  • Dr Reddys Laboratories' Payables amounted to $458.1 million in Q4 2025.
  • Over the past 5 years, Dr Reddys Laboratories' Payables peaked at $849.6 million during Q1 2025, and registered a low of -$29.5 million during Q3 2022.
  • Its 5-year average for Payables is $332.6 million, with a median of $331.9 million in 2023.
  • Per our database at Business Quant, Dr Reddys Laboratories' Payables plummeted by 14432.05% in 2022 and then surged by 84079.55% in 2025.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Payables stood at $326.9 million in 2021, then fell by 3.04% to $317.0 million in 2022, then plummeted by 82.55% to $55.3 million in 2023, then fell by 11.34% to $49.0 million in 2024, then skyrocketed by 834.23% to $458.1 million in 2025.
  • Its last three reported values are $458.1 million in Q4 2025, $461.3 million for Q3 2025, and $72.5 million during Q2 2025.